About
ElmediX

Cancer remains a major health issue worldwide. Treatment of local disease has advanced significantly, but systemic, metastasized disease remains an important challenge.

Small molecules and immunotherapy are promising but only for a small percentage of patients.

Our Story

ElmediX was founded in 2015 as a spin-off of the University of Antwerp with one goal: to develop a disruptive solution for (pancreatic) cancer and other life-threatening diseases. Co-founders professor dr. John-Paul Bogers (CEO, professor in histology and cell biology) and ir. Johan Van den Bossche (CTO, serial entrepreneur) are still active in the company.

With a family of 5 patents covering the technology platform, following a well-defined strategy set out by the patent bureau IPLodge, ElmediX has obtained a strong IP position throughout the world (EU, USA, China and Hong-Kong). The company also holds the trademarks for ElmediX® in the same regions.

Timeline

2015

2015

ElmediX was founded in 2015 in Haasrode
2017

2017

Start minipig (Aachener) study trial in 2017
2018

2018

Additional office in Mechelen opened in 2018
2018

2018

Start dog study trial phase I in 2018
2020

2020

First-In-Human Study Approval Ethical Committee University Hospital of Antwerp (UZA) in June 2020
2020

2020

Approval Federal Agency for Medicines and Health Products (FAMHP) in July 2020
2020

2020

Start First-In-Human clinical trial in October 2020

Our Mission

Our goal is to improve the quality-of-life and to extend the lives of millions of patients worldwide through the application of our innovative technologies. We want to provide remarkable solutions which deliver value to patients and their families, doctors and nursing staff and hospitals.

Our aim is to recognize the individual value and commitment of all our employees by creating a working environment which offers room for personal satisfaction, security, correct remuneration and career opportunities.

We strive for the highest possible reliability and quality of our products. Our wish is to be recognized as “best-in-class” for the delivery of high-quality innovative products which we offer to our partners as a commercial opportunity. We aspire a good long-term strategic collaboration with all our partners.

We intend to make a reasonable profit from our business activities, so that we can meet our commitments, continue our growth and achieve our goals.

Our mission encourages us to contribute to human well-being and to our community, which also includes environment friendly measures. We strive to develop products that have a minimal impact on the environment in terms of design, raw materials, production, packaging, recycling and waste disposal.

Our Values

Strong values define our corporate culture and help us fulfill ElmediX’ mission and vision.

Reliability

As a company, we want to represent a stable, caring and reliable partner for all our stakeholders: patients, healthcare providers and hospitals, suppliers, employees and shareholders.

Integrity

We strive to take our responsibilities as a company with a high sense of citizenship. It promotes respect, fairness, transparency and justice with which we lead our professional practices and determines our positive contribution to society.

Teamwork

As a team, we work constructively together on the same goal in an open positive atmosphere, with respect for each other, striving for a pleasant, motivating and inspiring working environment.

Engagement

Commitment, taking responsibility, initiative and continuous improvement are deeply embedded in our corporate culture.

Management Team

CTO & co-founder

ir. Johan Van den Bossche

Johan Van den Bossche (CTO) is a serial entrepreneur. He co-founded Krypton Electronic Engineering and managed the company until its sale in 2005 to Metris (today NIKON Metrology). Since then, he has been involved in several new ventures: LAB Motion Systems (Air bearings), Vesalius Medical Technologies (Bursitis treatment), Xenomatix (Lidar for autonomous driving), Faromatics (Robotics & AI for farm automation, Barcelona), Saint start-up (Start-up Data Analytics, Athens) and Mauhn (AGI).

Johan graduated from KUL as Electrotechnical engineer and worked on a PhD in robotics at PMA, Leuven and NIST, Washington DC.

CMO

Oleg Rudenko, MD, MSc EE

Oleg Rudenko (CMO) studied Electrotechnical Engineering at the Technical University Delft and Medicine at the University of Antwerp.

Oleg worked in anesthesiology at Antwerp University Hospital.

Oleg was Clinical research physician at SGS until he started at ElmediX.

Finance & HR Manager

Carine Eliaerts

Finance professional with +25 years of experience in national and international companies, with strong skills in financial accounting, reporting, as well as budget management and business administration.

As a hands-on and achievement oriented person, her focus is on implementing, improving and supporting a functional finance reporting and analysis system, in alignment with the goals and mission of the company.

Carine joined ElmediX in December 2019.

Advisory Board

Columbia University, Head of GI Oncology, USA

Prof. Dr. Susan E. Bates

Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda. MD Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015.
Duke University, USA

Prof. dr. Mark Dewhirst

Mark W. Dewhirst, DVM, PhD, FASTRO, FAAAS is the Emeritus Gustavo S. Montana Professor of Radiation Oncology, former Associate Dean for Faculty Mentoring and Vice Director for Basic Science in the Duke Cancer Institute. Dr. Dewhirst has research interests in tumor hypoxia, angiogenesis, hyperthermia and drug transport and had NIH funding to study these subjects for more than 30 years. He has >600 peer-reviewed publications, book chapters and reviews. His works have been cited more than 40,000 times in the literature. He has given named lectures at the University of Western Ontario, Thomas Jefferson University, Stanford University, the Norwegian Radium Hospital in Oslo, The University of Pennsylvania and the New Zealand Cancer Society. He received the Alumni of the Year Award from Colorado State University College of Veterinary Medicine. He received the Failla Medal from the Radiation Research Society in 2008, the Eugene Robinson award for excellence hyperthermia research in 1992 and a similar award from the European Society for Hyperthermic Oncology in 2009. He received the Gold Medal Award from the American Society for Radiation Oncology in 2012. He is also a Fellow of the American Association for the Advancement of Science. He is a Senior Editor of Cancer Research and Editor-in-Chief of the International Journal of Hyperthermia. He graduated from the University of Arizona in 1971 with a degree in Chemistry and Colorado State University in 1975 and 1979 with DVM and PhD degrees, respectively.
MD, PhD, Professor in Clinical Oncology, Shanghai Jiaotong University

Prof. Liwei Wang

Director of Pancreatic Cancer Center of Shanghai Jiaotong University, Oncology Department Director of Renji Hospital, Chairman of MDT Expert Committee of Renji Hospital.

Chairman of Pancreatic Cancer Expert Committee of Chinese Society of Clinical Oncology, Committee of Oncology Branch of Chinese Medical Association and Group Leader of Pancreatic Oncology, Vice Chairman of the Pancreatic Disease Professional Committee of the Chinese Research Hospital Association.

Presided over the first “Chinese Expert Consensus on the Diagnosis and Treatment of Pancreatic Cancer” and the first “CSCO Guidelines for Pancreatic Cancer Diagnosis and Treatment” of the Chinese Society of Clinical Oncology.

The associate editor of “Journal of Pancreatology”, the editorial board member of “Cancer Research”, “JHO”, “Tumor”, “Clinical Oncology” and other journals.

Published more than 100 SCI papers with more than 1,000 times citation.

Hyperthermia specialist, MC Erasmus, Rotterdam, Netherlands

Dr. Jacoba van der Zee

Studied medicine in Amsterdam and Leiden and achieved her Ph.D. (subject Whole Body Hyperthermia) at the Erasmus University in Rotterdam in 1987. Is since 1978 engaged in clinical research on hyperthermia in addition to radiotherapy or chemotherapy at the Erasmus MC Cancer Institute. Is (co)author of >130 peer-reviewed publications on several types of hyperthermia (whole body, local, loco-regional, interstitial, and perfusion). Was president of the European Society for Hyperthermic Oncology from 1996 to 1999. Is winner of several awards among which the Lund Science Award (1994), the ESHO-BSD Award (1999), and the Eugene Robinson Award. Was appointed Knight in the Order of Orange-Nassau by the Queen of the Netherlands in 2010 for her contributions in the field of hyperthermia.
Co-founder Krypton NV, CEO GrindoSonic

Dr. ir. Alex Van den Bossche

Dr. ir. Alex Van den Bossche has done research work in medical implantable devices in the framework of his doctoral thesis on the "Automatic Implantable Defibrillator". He co-founded Krypton NV, a KU Leuven high-tech spin-off company specialising in industrial optical metrology. He served as managing director for 15 years until the successful trade sale of the company to Metris/Nikon. He co-founded Allegro Investment Fund, specialising in technology-based early stage Private Equity. Since 5 years he acquired GrindoSonic, a KULeuven spin-off specialising in measurement systems for material characterisation and Quality Control where he serves as CEO.

Our Team

Since its inception in 2015, ElmediX has brought together a highly skilled team. In the (near) future, our team will be expanded with other enthusiastic colleagues. Interested in joining the team? See our current vacancies.